Thalidomide in multiple myeloma: past, present and future (Q36616493)

15 August 2017

1 reference

title

Thalidomide in multiple myeloma: past, present and future (English)

1 reference

15 August 2017

0 references

1 reference

Jean-Luc Harousseau

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

577-589

1 reference

Thalidomide in multiple myeloma: current status and future prospects

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Thalidomide is an inhibitor of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Bone marrow angiogenesis and progression in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Thalidomide analogs as emerging anti-cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Clinical pharmacology of thalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Treatment of plasma cell dyscrasias with thalidomide and its derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Thalidomide and dexamethasone for resistant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Thalidomide and dexamethasone combination for refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Thalidomide as initial therapy for early-stage myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

New treatment strategies for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Treatment options in metastatic renal carcinoma: an embarrassment of riches

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Myelopoiesis in the zebrafish, Danio rerio.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Low-dose thalidomide in myeloma: efficacy and biologic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.577

21 January 2018

Identifiers

DOI

10.2217/14796694.2.5.577

1 reference

15 August 2017

1 reference